Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

被引：0

作者：

Jeroen P. Jansen

Sabine Gaugris

Ernest H. Choy

Andrew Ostor

Julian T. Nash

Wiro Stam

机构：

[1] Mapi Values,Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology

[2] Outcome Research,Department of Rheumatology

[3] Merck & Co.,Department of Rheumatology, Royal National Orthopaedic Hospital

[4] Inc.,undefined

[5] GKT School of Medicine,undefined

[6] King’s College Hospital,undefined

[7] Addenbrooke’s Hospital,undefined

[8] Stanmore Hospital,undefined

[9] Mapi Values,undefined

来源：

PharmacoEconomics | 2010年 / 28卷

关键词：

Ankylose Spondylitis; Celecoxib; Naproxen; Etoricoxib; Bath Ankylose Spondylitis Disease Activity Index;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Objective: To evaluate the cost effectiveness of etoricoxib (90mg/day) relative to celecoxib (200 or 400mg/day), and the non-selective NSAIDs naproxen (1000mg/day) and diclofenac (150 mg/day) in the initial treatment of ankylosing spondylitis (AS) from the UK NHS perspective.

引用

页码：323 / 344

页数：21

共 42 条

[41] Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial
Kara Bickham
Alan J. Kivitz
Anish Mehta
Nancy Frontera
Sandhya Shah
Paul Stryszak
Zoran Popmihajlov
Paul M. Peloso
BMC Musculoskeletal Disorders, 17
[42] The Effectiveness of a Weak Opioid Medication versus a Cyclo-oxygenase-2 (COX-2) Selective Non-steroidal Anti-inflammatory Drug in Treating Flare-up of Chronic Low-back Pain: Results from Two Randomized, Double-blind, 6-week Studies
O'Donnell, J. B.
Ekman, E. F.
Spalding, W. M.
Bhadra, P.
McCabe, D.
Berger, M. F.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2009, 37 (06) : 1789 - 1802

← 1 2 3 4 5 →